A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL

Open source

DOI: 10.1097/mph.0b013e3182a8f58f
Published: 2014 Aug
Container: Journal of pediatric hematology/oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/mph.0b013e3182a8f58f,
  title = {A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.},
  author = {Raetz EA and Morrison D and Romanos-Sirakis E and Gaynon P and Sposto R and Bhojwani D and Bostrom BC and Brown P and Eckroth E and Cassar J and Malvar J and Buchbinder A and Carroll WL},
  year = {2014},
  journal = {Journal of pediatric hematology/oncology},
  doi = {10.1097/mph.0b013e3182a8f58f},
  url = {https://doi.org/10.1097/mph.0b013e3182a8f58f}
}

RIS

TY  - JOUR
TI  - A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
AU  - Raetz EA
AU  - Morrison D
AU  - Romanos-Sirakis E
AU  - Gaynon P
AU  - Sposto R
AU  - Bhojwani D
AU  - Bostrom BC
AU  - Brown P
AU  - Eckroth E
AU  - Cassar J
AU  - Malvar J
AU  - Buchbinder A
AU  - Carroll WL
PY  - 2014
JO  - Journal of pediatric hematology/oncology
DO  - 10.1097/mph.0b013e3182a8f58f
UR  - https://doi.org/10.1097/mph.0b013e3182a8f58f
ER  -

APA

EA, R., D, M., E, R., P, G., R, S., D, B., BC, B., P, B., E, E., J, C., J, M., A, B., & WL, C. (2014). A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.. Journal of pediatric hematology/oncology. https://doi.org/10.1097/mph.0b013e3182a8f58f

Source records

pubmed · retrieved 2026-09-26T21:20:16.445Z
europe-pmc · retrieved 2026-09-26T21:20:16.446Z